{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-301206","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.071285+00:00","generated_at":"2026-06-07T09:10:11.989498+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Dianthus recasts audited financials for legacy OpCo; net loss $28.5M in 2022, going concern noted","bullets":["Net loss of $28.5M in 2022, $13.1M in 2021; accumulated deficit $45.9M at Dec 31, 2022.","Revenue from related party Zenas $6.4M in 2022, $1.5M in 2021; R&D expense $29.4M.","Cash and investments $75.5M; going concern doubt due to insufficient capital for 12 months.","Merger with Magenta closed Sep 11, 2023, accounted as reverse recapitalization; all historical shares restated at 0.2181 exchange ratio."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-301206","json":"https://secwatch.observer/filing/0001193125-23-301206.json","markdown":"https://secwatch.observer/filing/0001193125-23-301206.md","text":"https://secwatch.observer/filing/0001193125-23-301206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523301206/0001193125-23-301206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523301206/d639778d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:10:11.989498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}